Cross-over Analysis of the Control of Coronary Risk Factors and Level of Platelet Inhibition With a Polypill

Who is this study for? Patients with coronary artery disease
What treatments are being studied? Acetylsalicylic acid+Ramipril+Atorvastatin
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Open-label, randomized, cross-over study conducted in a single center, applied to patients receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and atorvastatin for indication of secondary prevention according to clinical practice, with objective of analyzing the level of systolic blood pressure and LDL-cholesterol in the same patient in 2 different periods: one under treatment of 3 months with the polypill and another of 3 months with the components separately.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients over 18 years of age. Patients under treatment with the Trinomia® polypill in any of its presentations for indication of secondary prevention and who can make the 6 visits necessary to complete the study. Patients who sign the Informed Consent.

Locations
Other Locations
Spain
Hospital Universitario de Cabueñes
RECRUITING
Gijón
Contact Information
Primary
Iñigo Lozano Martinez-Luengas, MD, PHD
inigo.lozano@gmail.com
+34630901145
Time Frame
Start Date: 2022-10-14
Estimated Completion Date: 2026-04-30
Participants
Target number of participants: 88
Treatments
Experimental: Polypill
Patients will be receiving the polypill at the adequate doses during 3 months
Active_comparator: Drugs taken separately
Patients will be receiving during 3 months the same components and at the same doses than with the polypill
Related Therapeutic Areas
Sponsors
Leads: Fundación EPIC

This content was sourced from clinicaltrials.gov